Nandini Tandon is a member of the board of C21 BioVentures. A venture capital investor in Silicon Valley since 2002, Tandon has been closely involved with more than 12 new technology-based ventures. Five of them were acquired within a few years of investment and several have become public companies. Her focus is on health-care and life science investments. Until recently, Tandon was managing director at Lumira Capital. Prior to Lumira, Tandon was a partner with RBC Capital Partner and launched RBC's U.S. life science venture capital presence. She has held senior positions with Zyomyx Inc., Hyseq Inc., Chiron Corp., Glaxo Wellcome and the Microelectronics Center of North Carolina, where she received a semiconductor patent. Tandon serves on the board of directors of two Silicon Valley companies, Spinal Kinetics and U-Systems. She received her Ph.D. in biochemistry from Duke University and her B.A. from Hollins University in Virginia.

Panel:
Investment Opportunities in Health Care - Whatever the Supreme Court Decides

Tweet